Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immunecombinations
Abstrakt
We conducted a multicenter retrospective observational study in metastatic renal cell carcinoma (mRCC) patients treated with first-line immune combinations from 55 centers in 19 countries.